Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

David Kadmon

Rheumatology Lincoln, RI Medical Doctor

NPI 1912946658 CMS profile 358919

132 Old River Rd, Suite B-2, Lincoln, RI 02865

Open in the dashboard

General payments

$12,749

241 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, David Kadmon of Lincoln, RI is reported in the CMS Open Payments database as having received $12,749 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $291 13
2022 General $733 30
2021 General $1,129 48
2020 General $2,665 64
2019 General $7,931 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Kadmon
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to David Kadmon were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year David Kadmon Rheumatology median Middle half National median
2019 $7,931 $744 $153–$2,687 $163
2020 $2,665 $462 $98–$2,027 $114
2021 $1,129 $531 $101–$2,153 $132
2022 $733 $627 $125–$2,303 $149
2023 $291 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Regeneron Pharmaceuticals, Inc. $6,576 11 payments
  2. UCB, Inc. $1,865 29 payments
  3. Amgen Inc. $1,108 51 payments
  4. Janssen Biotech, Inc. $750 32 payments
  5. GlaxoSmithKline, LLC. $725 32 payments
  6. E.R. Squibb & Sons, L.L.C. $307 14 payments
  7. Horizon Therapeutics plc $228 8 payments
  8. AbbVie, Inc. $199 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $180 11 payments
  10. Organon LLC $157 6 payments
  11. Other $654 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $6,695 2 payments
  2. Food and Beverage $5,180 229 payments
  3. Travel and Lodging $837 4 payments
  4. Education $37 6 payments
Products named General payments · program years 2019–2023
  1. KEVZARA $6,647 15 payments
  2. SIMPONI ARIA $764 33 payments
  3. BENLYSTA $705 30 payments
  4. STELARA $580 25 payments
  5. Cimzia $570 28 payments
  6. Prolia $435 20 payments
  7. EVENITY $309 14 payments
  8. ORENCIA $307 14 payments
  9. SIMPONI $293 12 payments
  10. REMICADE $271 11 payments
  11. Other $2,454 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record